Source	Search strategy	Hits retrieved
CENTRAL	#1 Buerger*:TI,AB,KY 70 #2 MESH DESCRIPTOR Thromboangiitis Obliterans EXPLODE ALL TREES 16 #3 (thromboang* ADJ2 oblit*):TI,AB,KY 51 #4 (endangitis obliterans):TI,AB,KY 0 #5 Winiwarter:TI,AB,KY 0 #6 #1 OR #2 OR #3 OR #4 OR #5 95 #7 01/01/2015 TO 15/10/2019:CD 741000 #8 #6 AND #7 60	60
Clinicaltrials.gov	Buerger OR Buergers or Thromboangiitis Obliterans	2
ICTRP Search Portal	Buerger OR Buergers or Thromboangiitis Obliterans	16
Medline (Ovid MEDLINE® Epub Ahead of Print, In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE® Daily and Ovid MEDLINE®) 1946 to present	1 Buerger*.ti,ab. 2 exp Thromboangiitis Obliterans/ 3 (thromboang* adj2 oblit*).ti,ab. 4 endangitis obliterans.ti,ab. 5 Winiwarter.ti,ab. 6 1 or 2 or 3 or 4 or 5 7 randomized controlled trial.pt. 8 controlled clinical trial.pt. 9 randomized.ab. 10 placebo.ab. 11 drug therapy.fs. 12 randomly.ab. 13 trial.ab. 14 groups.ab. 15 or/7‐14 16 exp animals/ not humans.sh. 17 15 not 16 18 6 and 17 19 (2015* or 2016* or 2017* or 2018* or 2019*).ed. 20 18 and 19 21 from 20 keep 1‐48	48
Embase 1974 to present	1 Buerger*.ti,ab. 2 exp Thromboangiitis Obliterans/ 3 (thromboang* adj2 oblit*).ti,ab. 4 endangitis obliterans.ti,ab. 5 Winiwarter.ti,ab. 6 1 or 2 or 3 or 4 or 5 7 randomized controlled trial/ 8 controlled clinical trial/ 9 random$.ti,ab. 10 randomization/ 11 intermethod comparison/ 12 placebo.ti,ab. 13 (compare or compared or comparison).ti. 14 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab. 15 (open adj label).ti,ab. 16 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab. 17 double blind procedure/ 18 parallel group$1.ti,ab. 19 (crossover or cross over).ti,ab. 20 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant$1)).ti,ab. 21 (assigned or allocated).ti,ab. 22 (controlled adj7 (study or design or trial)).ti,ab. 23 (volunteer or volunteers).ti,ab. 24 trial.ti. 25 or/7‐24 26 6 and 25 27 (2015* or 2016* or 2017* or 2018* or 2019*).dc. 28 26 and 27 29 from 28 keep 1‐57	57
CINAHL	S22 S6 AND S21 S21 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 S20 MH "Random Assignment" S19 MH "Triple‐Blind Studies" S18 MH "Double‐Blind Studies" S17 MH "Single‐Blind Studies" S16 MH "Crossover Design" S15 MH "Factorial Design" S14 MH "Placebos" S13 MH "Clinical Trials" S12 TX "multi‐centre study" OR "multi‐center study" OR "multicentre study" OR "multicenter study" OR "multi‐site study" S11 TX crossover OR "cross‐over" S10 AB placebo* S9 TX random* S8 TX trial* S7 TX "latin square" S6 S1 OR S2 OR S3 OR S4 OR S5 S5 TX Winiwarter S4 TX endangitis obliterans S3 TX thromboang* N2 oblit* S2 (MH "Thromboangiitis Obliterans") S1 TX Buerger*	44